ari hakimi

Kidney Cancer surgeon/scientist @MSKCancerCenter . Co-leader of Translational Kidney Cancer Program and Assistant PD @urologymsk Tweets my own.

[Eli Van Allen @VanAllenLab]

In our latest, we continued multi-omic exploration of GI neuroendocrine tumors, finding potential organ-specific molecular programs and microenvironmental niches - congrats Julie Karam @SamHoffmanMed et al! @DanaFarber @broadinstitute @jclinicalinvest https://t.co/Nss6nBHX4t

[ari hakimi @arihakimi]

@KSusztak Happy birthday!!

[Uromigos @Uromigos]

@arihakimi joins us with Lyn Voung to discuss a recent #cancercell paper which explored the impact of TKI-induced hypoxia in their RCC mouse model.

https://t.co/kEfYiyfAiZ

[ari hakimi @arihakimi]

Wonderful evening with our amazing @UroOnc fellows and families. Lots of little babies!!

[ari hakimi @arihakimi]

Great time at @kidneycan meeting talking science and collaborations with experts from all over! #kcrs26

[Wesley Yip @WesleyYipMD]

Love this start to #KCRS26 from Craig Thompson @MSKCancerCenter.

Bonus: 👋 hi from the mural from me and @UrologyMSK/@AmerUrological USMART Program mentor @AriHakimi

[ari hakimi @arihakimi]

Amazing keynote from Craig Thompson from @MSKCancerCenter to lead of the @kidneycan meeting!

[ari hakimi @arihakimi]

Best meeting of the year!!

[Toni Choueiri, MD @DrChoueiri]

The night before #KCRS26,
The premier meeting of Kidney Cancer Research @kidneycan @HHammersMD @DrRanaMcKay @arihakimi @montypal

[Toni Choueiri, MD @DrChoueiri]

The night before #KCRS26,
The premier meeting of Kidney Cancer Research @kidneycan @HHammersMD @DrRanaMcKay @arihakimi @montypal

[Sean Fletcher @SeanFletcherMD]

Thanks @urogoldjournal for publishing our work on MRI-targeted biopsy for suspected local recurrence after RP. Biopsy prior to salvage RT (esp in equivocal cases) can guide dose escalation strategies @BehfarEhdaieMD @BCottaMD @HimanshuNagarMD @UrologyMSK

https://t.co/4kcO33EOet

[Aisha Shaikh @aishaikh]

Excited to share our review in @NatRevUrol “Urolithiasis in Patients with Cancer” @arihakimi

We discuss unique mechanisms driving stone disease in cancer patients, bidirectional relationship between cancer & urolithiasis, management of urolithiasis in this pt population
https://t.co/3YkfzdEBl2

[ari hakimi @arihakimi]

Very grateful for the honor and to get to work with such a dedicated, kind and talented group of fellows. So excited for what’s to come!

[Nick Pickersgill, MD @NickPickersgill]

Steak dinner to celebrate @arihakimi Teacher of the Year @UrologyMSK. Well deserved!

[Nick Pickersgill, MD @NickPickersgill]

Steak dinner to celebrate @arihakimi Teacher of the Year @UrologyMSK. Well deserved!

[ari hakimi @arihakimi]

@WCMUrology @WeillCornell @nyphospital @mostrasser @LinaPosadaCald @leodre @RodriguezMDUrol @UroResidency @AmerUrological @NYSAUA @KyleBlumMD Amazing group!!

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

Congratulations to Dr. Martin Weiser, who has been selected to serve serve as the next Chair of the Department of Surgery at MSK.

Dr. Weiser currently holds the Stuart H.Q. Quan Chair in Colorectal Surgery, is a world-renowned academic colorectal surgeon, and has held a number of important leadership roles in his 25 years on the faculty at MSK, including serving for the past 10 months as the Acting Department Chair.

Join us in welcoming Dr. Weiser to the role of Chair of the Department of Surgery by commenting below. 👏

[ari hakimi @arihakimi]

Conclusion: ccRCC begins as a pseudohypoxic, vascular tumor. VEGFR-TKIs trigger hypoxia, driving tumor control and recruitment of SPP1⁺ TAMs. However, persistent hypoxia can ultimately promote resistance and mets linking response and failure through the same biological process.

[ari hakimi @arihakimi]

Why do VEGFR-TKI + IO combinations produce impressive responses in ccRCC but often fail to achieve the long-term durability seen with dual checkpoint blockade? Check out our lab's latest in @Cancer_Cell led by the incredible Lyn Vuong!
https://t.co/ASvkCpDzQW

[ari hakimi @arihakimi]

Across clinical trials and real-world cohorts, pretreatment hypoxia predicted poorer outcomes. In contrast, on-treatment hypoxia-associated TAM programs reflected therapeutic activity. Timing matters: baseline hypoxia and treatment-induced hypoxia are biologically distinct.